down arrow

Tenaya Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87990A1060
USD
0.70
0.03 (4.87%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.670.71

52 Week

0.362.35
Valuation
Technical
Day's Volume

CASH

4.94 M

Shareholding (Jun 2025)

FII

2.81%

Held by 35 FIIs

DII

57.83%

Held by 30 DIIs

Promoter

15.60%

How big is Tenaya Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Tenaya Therapeutics, Inc. has a market capitalization of 93.37 million, with net sales of 0.00 million and a net profit of -105.76 million over the latest four quarters. The company reported shareholder's funds of 92.85 million and total assets of 123.33 million as of Dec 24.

Market Cap: As of Jun 18, Tenaya Therapeutics, Inc. has a market capitalization of 93.37 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Tenaya Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -105.76 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 92.85 million and total assets of 123.33 million.

Read More

What does Tenaya Therapeutics, Inc. do?

22-Jun-2025

Tenaya Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $27 million and a market cap of $93.37 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -88.58%.

Overview:<BR>Tenaya Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -27 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 93.37 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.71<BR>- Return on Equity: -88.58%<BR>- Price to Book: 0.78<BR><BR>Contact Details:<BR>No Company Details Available.

Read More

Is Tenaya Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Tenaya Therapeutics, Inc. shows a mildly bearish trend with mixed technical signals, underperforming the S&P 500 significantly year-to-date and over the past year.

As of 21 August 2025, the technical trend for Tenaya Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is bullish, but the weekly RSI is bearish, indicating mixed signals. The daily moving averages are mildly bearish, while the monthly Bollinger Bands show a mildly bearish stance. The KST is bullish on a weekly basis but bearish monthly, and the Dow Theory indicates a mildly bullish trend on the weekly chart with no trend monthly. <BR><BR>In terms of performance, the stock has returned -7.69% year-to-date compared to the S&P 500's 12.22%, and it has significantly underperformed over the past year with a return of -34.65% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 228 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.69

stock-summary
Return on Equity

-99.79%

stock-summary
Price to Book

2.29

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-23 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-50.32%
0%
-50.32%
6 Months
21.09%
0%
21.09%
1 Year
-50.32%
0%
-50.32%
2 Years
-72.42%
0%
-72.42%
3 Years
-65.66%
0%
-65.66%
4 Years
-96.48%
0%
-96.48%
5 Years
0%
0%
0.0%

Tenaya Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-163.27%
EBIT to Interest (avg)
-100.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
90.34%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.86
EV to EBIT
-0.16
EV to EBITDA
-0.18
EV to Capital Employed
0.52
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-322.41%
ROE (Latest)
-88.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 33 Schemes (23.76%)

Foreign Institutions

Held by 35 Foreign Institutions (2.81%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 20.75% vs 11.71% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.00",
          "val2": "-28.70",
          "chgp": "23.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.30",
          "val2": "-29.40",
          "chgp": "20.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.48% vs -0.32% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-107.50",
          "val2": "-122.50",
          "chgp": "12.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-111.10",
          "val2": "-124.10",
          "chgp": "10.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-22.00
-28.70
23.34%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-23.30
-29.40
20.75%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 20.75% vs 11.71% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-107.50
-122.50
12.24%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-111.10
-124.10
10.48%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 10.48% vs -0.32% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Tenaya Therapeutics, Inc. stock-summary
stock-summary
Tenaya Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."